Screener
Tarsus Pharmaceuticals, Inc. TARS Total Revenue
Total Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Product sales, net | $173,912 | $102,660 | $319,299 | $180,995 |
| License fees and collaboration revenue | — | — | 16,667 | — |
| Total revenues | 173,912 | 102,660 | 335,966 | 180,995 |
| Operating expenses: | ||||
| Cost of sales | 12,113 | 6,237 | 21,509 | 11,448 |
| Research and development | 31,010 | 15,594 | 53,361 | 30,003 |
| Selling, general and administrative | 150,697 | 103,013 | 287,126 | 188,008 |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s total revenue?
- Tarsus Pharmaceuticals, Inc. (TARS) reported total revenue of $173.91M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s total revenue changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s total revenue increased by 69.4% year-over-year, from $102.66M to $173.91M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s total revenue?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s total revenue has grown at a 67.7% compound annual growth rate (CAGR), from $57.03M to $451.36M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude